267 related articles for article (PubMed ID: 25698407)
1. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?
Bokhorst LP; Venderbos LD; Schröder FH; Bangma CH; Steyerberg EW; Roobol MJ
J Urol; 2015 Aug; 194(2):336-42. PubMed ID: 25698407
[TBL] [Abstract][Full Text] [Related]
2. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
3. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
4. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
[TBL] [Abstract][Full Text] [Related]
5. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
6. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam.
Bul M; van Leeuwen PJ; Zhu X; Schröder FH; Roobol MJ
Eur Urol; 2011 Apr; 59(4):498-505. PubMed ID: 21334136
[TBL] [Abstract][Full Text] [Related]
8. Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.
Bokhorst LP; Kranse R; Venderbos LD; Salman JW; van Leenders GJ; Schröder FH; Bangma CH; Roobol MJ;
Eur Urol; 2015 Aug; 68(2):179-82. PubMed ID: 25457496
[TBL] [Abstract][Full Text] [Related]
9. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
10. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
Wever EM; Draisma G; Heijnsdijk EA; Roobol MJ; Boer R; Otto SJ; de Koning HJ
J Natl Cancer Inst; 2010 Mar; 102(5):352-5. PubMed ID: 20142584
[TBL] [Abstract][Full Text] [Related]
12. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
[TBL] [Abstract][Full Text] [Related]
13. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
[TBL] [Abstract][Full Text] [Related]
16. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
Van der Meer S; Kollen BJ; Hirdes WH; Steffens MG; Hoekstra-Weebers JE; Nijman RM; Blanker MH
BJU Int; 2013 Jul; 112(1):26-31. PubMed ID: 23465178
[TBL] [Abstract][Full Text] [Related]
17. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
18. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.
van der Cruijsen-Koeter IW; van der Kwast TH; Schröder FH
J Natl Cancer Inst; 2003 Oct; 95(19):1462-6. PubMed ID: 14519752
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]